The TheraP trial restricted inclusion to PSMA positivity with an SUVmax (the maximum standardised uptake value) of at least 20 at a site of disease and SUVmax > 10 at all other measurable metastatic disease [119]. The gene discussed is FOLH1; the disease is metastatic neoplasm.